LPTX
Closed
Leap Therapeutics Inc
0.2963
-0.0006 (-0.20%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.2969
Day's Range: 0.271 - 0.3195
Send
sign up or login to leave a comment!
When Written:
0.31
Leap Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing targeted therapies for cancer. The company's pipeline includes several investigational drugs that target specific cancer-related proteins and pathways.
Leap's lead drug candidate is DKN-01, which is being developed for the treatment of gastric and gastroesophageal junction cancer. The company is also developing TRX518, a monoclonal antibody that targets the glucocorticoid-induced TNFR-related protein (GITR) pathway, for the treatment of solid tumors.
In addition to its internal drug development efforts, Leap has collaborations with other companies and academic institutions to advance its research and development programs.
Leap Therapeutics Inc was founded in 2011 and is headquartered in Cambridge, Massachusetts. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "LPTX."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Leap's lead drug candidate is DKN-01, which is being developed for the treatment of gastric and gastroesophageal junction cancer. The company is also developing TRX518, a monoclonal antibody that targets the glucocorticoid-induced TNFR-related protein (GITR) pathway, for the treatment of solid tumors.
In addition to its internal drug development efforts, Leap has collaborations with other companies and academic institutions to advance its research and development programs.
Leap Therapeutics Inc was founded in 2011 and is headquartered in Cambridge, Massachusetts. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol "LPTX."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








